辰欣药业股份有限公司 关于持股5%以上股东减持股份计划完成暨减持股份结果公告

Group 1 - The major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd. (Stone Four Pharmaceutical), held 27,661,441 shares of Chenxin Pharmaceutical, accounting for 6.11% of the total share capital before the reduction plan [1] - The reduction plan announced on August 30, 2025, indicated that Stone Four Pharmaceutical intended to reduce its holdings by up to 4,527,000 shares, which is 1.00% of the total shares [1] - As of September 22, 2025, Stone Four Pharmaceutical reduced its holdings by 1,000,000 shares, bringing its total holdings down to 26,661,441 shares, which is 5.89% of the total share capital [2] Group 2 - By September 24, 2025, Stone Four Pharmaceutical had completed its reduction plan, having cumulatively reduced its holdings by 4,520,000 shares, representing 0.998% of the total share capital [2][4] - The actual reduction was consistent with the previously disclosed reduction plan, and the plan was fully implemented without any early termination [4]